New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 21, 2014
08:11 EDTTEVA, ARNAArena Pharma' subsidiary enters into agreement for Belviq with Teva subsidiary
Arena Pharmaceuticals (ARNA) announced that its wholly owned subsidiary, Arena Pharmaceuticals, has entered into an exclusive marketing and supply agreement for BELVIQ with Teva Pharmaceutical Industries Limited's (TEVA) local Israeli subsidiary, Abic Marketing Limited. Under the agreement, Arena granted Abic the rights to market and distribute BELVIQ in Israel for weight loss or weight management in obese and overweight patients, subject to regulatory approval by the State of Israel Ministry of Health.
News For ARNA;TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 21, 2015
09:10 EDTARNAArena Pharmaceuticals 21M share Spot Secondary priced at $5.00
Subscribe for More Information
08:51 EDTARNAArena Pharma sells 21M shares to Leucadia's Jefferies and Piper Jaffray
Arena Pharmaceuticals (ARNA) has sold 21M shares of common stock to Jefferies, a subsidiary of Leucadia (LUK) and to Piper Jaffray (PJC) as underwriters for its previously announced public offering. The offering is expected to close on or about January 26. In addition, Arena has granted the underwriters a 30-day option to purchase up to an aggregate of 3M additional shares of common stock. Arena anticipates using the net proceeds from the offering for the clinical and preclinical development of drug candidates, for discovery research for new drug candidates, and for general corporate purposes.
08:38 EDTTEVAMomenta announces Supreme Court decision to remand generic Copaxone back to CAFC
Subscribe for More Information
05:58 EDTARNAStocks with implied volatility below IV index mean; BBRY ARNA
Subscribe for More Information
January 20, 2015
18:30 EDTARNAOn The Fly: After Hours Movers
Subscribe for More Information
17:19 EDTARNAArena Pharmaceuticals cash, cash equivalents as of Dec. 31 $163.2M
Subscribe for More Information
16:05 EDTARNAArena Pharmaceuticals files to sell common stock, no amount given
Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering.
14:37 EDTTEVATeva generic competition to Copaxone pushed out by ruling, says BMO Capital
Subscribe for More Information
12:56 EDTTEVAMylan says continues to believe '808 patent is 'invalid'
Subscribe for More Information
11:29 EDTTEVATeva says Supreme Court reverses circuit court judgment on Copaxone 20 mg/mL
Teva Pharmaceutical announced the U.S. Supreme Court’s decision in Teva Pharmaceuticals USA, Inc. et al. Petitioners v. Sandoz Inc. et al. that reversed the Federal Circuit Court’s judgment of invalidity of Teva’s ‘808 patent for COPAXONE 20 mg/mL. The Supreme Court remanded the case to the Federal Circuit for further review in light of the applicable standard the Supreme Court laid out for appellate review of claim construction. A ruling last year by the U.S. Court of Appeals for the Federal Circuit upheld four Teva patents that expired in May 2014, while invalidating the ‘808 patent that is set to expire on September 1, 2015. “We are encouraged by the U.S. Supreme Court’s Decision and look forward to the Federal Circuit’s review. We will continue to explore all available avenues to protect our intellectual property for COPAXONE 20mg/mL,” said Erez Vigodman, President and CEO of Teva. “There is currently no FDA-approved follow-on version of Teva’s COPAXONE. We are encouraged by the FDA’s willingness to date to have dialogue regarding the complexities of COPAXONE 20 mg/mL and the potential limitations and other unknowns of purported follow-on versions,” added Rob Koremans, MD, President and CEO of Global Specialty Medicines at Teva.
10:45 EDTTEVATeva spikes, retraces, after win in Copaxone patent case
Subscribe for More Information
10:40 EDTTEVAMomenta Pharma sinks after Supreme Court rules on Copaxone
Subscribe for More Information
10:35 EDTTEVATeva rises after patent ruling upheld by Supreme Court
The Supreme Court upheld a lower court ruling related to generic versions of Teva's Copaxone drug. In the ruling, the court wrote that "When reviewing a district court’s resolution of subsidiary factual matters made in the course of its construction of a patent claim, the Federal Circuit must apply a “clear error,” not a de novo, standard of review." Teva shares are up 1.5% to $58.58 in early trading after the ruling. Reference Link
09:10 EDTARNAArena sees Q4 Belviq sales down 35%-45% vs. Q3
Subscribe for More Information
06:08 EDTARNAStocks with implied volatility below IV index mean; BBRY ARNA
Subscribe for More Information
January 16, 2015
06:10 EDTARNAStocks with implied volatility below IV index mean; BBRY ARNA
Stocks with implied volatility below IV index mean; BlackBerry (BBRY) 63, Arena Pharmaceuticals (ARNA) 86 according to iVolatility.
January 15, 2015
06:04 EDTARNAStocks with implied volatility below IV index mean; ORCL ARNA
Subscribe for More Information
January 14, 2015
10:21 EDTARNAOptions with decreasing implied volatility
Subscribe for More Information
06:03 EDTARNAStocks with implied volatility below IV index mean; ORCL ARNA
Subscribe for More Information
January 13, 2015
06:02 EDTARNAStocks with implied volatility below IV index mean; ARNA LINE
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use